OCM
GILD icon

Osbon Capital Management’s Gilead Sciences GILD Stock Holding History

Osbon Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Hold
90
– – 0.01% 265
2026
Q1 		$12.5K Hold
90
– – 0.01% 267
2025
Q4 		$11K Buy
+90
New +$10.9K 0.01% 220

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osbon Capital Management's GILD Position: Q2 2026 in Review

Osbon Capital Management held its Gilead Sciences (GILD) position steady in Q2 2026 at 90 shares worth $11.4K. The position accounts for 0.01% of the portfolio, ranked #265.

Osbon Capital Management first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.5K in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Osbon Capital Management held 90 shares of Gilead Sciences worth $11.4K as of Q2 2026.
  • Osbon Capital Management left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.01% of Osbon Capital Management's portfolio in Q2 2026, its #265 holding.
  • Osbon Capital Management first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Osbon Capital Management's Gilead Sciences position peaked at $12.5K in Q1 2026.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Osbon Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.